“Safe” is not an adjective in cross-border care — it is a set of checkable indicators: hospital and physician licensure, annual case volume, capacity to manage complications, whether the drug is approved by the regulator, and which procedure applies if something goes wrong.
Who oversees oncology care in China
Chinese hospitals are registered and graded by health authorities under the Regulation on the Management of Medical Institutions; Tier-3A is the top grade in the hospital review system. Oncology quality is additionally constrained by national and provincial cancer quality-control centres, with standards issued by professional bodies such as the Chinese Medical Association. Drugs and devices require NMPA approval; unapproved products cannot be used routinely.
The hard indicators we verify for every patient
- Hospital grade and oncology accreditation, plus in-house authorisation to perform the specific technique;
- Recent annual volume for the department and cumulative case counts for the procedure (for example transplant-unit capacity or cumulative proton cases);
- Complication capacity: ICU, blood-product supply, infection control and multidisciplinary review;
- Whether the drug or product is on the NMPA approval list, and whether the indication matches;
- International patient experience: countries previously served, language support and record-translation workflow.
What patients can check themselves
- The hospital website for grade, departments and disclosed annual volumes; licensing records published by health authorities;
- NMPA public approvals for drugs and devices — check the product name and indication;
- Published annual or quality reports for survival and complication rates.
This note explains how to verify, and is neither medical advice nor a recommendation of any institution. Whether and how to treat is decided by the licensed physicians of the treating hospital.